Abstract
In recent years, clinical applications of recombinantly produced bioactive proteins such as cytokines have attracted attention. However, since these recombinant proteins are rather unstable in vivo, their clinical use as therapeutic agents requires frequent administration at a high dosage. This regimen disrupts homeostasis and results in severe side effects. To overcome these problems, bioactive proteins have been conjugated with water-soluble synthetic (WSS) polymeric carriers. Chemical modification of a protein with a WSS polymeric carrier (bioconjugation) regulates tissue distribution, resulting in a selective increase in its desirable therapeutic effects and a decrease in undesirable side effects. Among several drug delivery system (DDS) technologies, bioconjugation has been recognized as one of the most efficient methods for improving therapeutic potency of proteins. However, for further enhancement of the therapeutic potency and safety of conjugated bioactive proteins, more precise regulation of the in vivo behavior of each protein is necessary for selective expression of its therapeutic effect. Therefore, alternative WSS polymeric modifiers in which new functions such as targeting and controlled release of drugs can be added are required for further development of bioconjugated drugs. Recently, we have synthesized a novel polymeric drug carrier, poly(vinylpyrrolidone-co-dimethyl maleic anhydride) [PVD], which was a powerful candidate drug carrier for cancer therapy. In this review, we introduce useful information that enabled us to design polymeric drug carriers and their application for protein therapy.
Keywords: Polyethylene glycol (PEG), bioconjugation, drug delivery system (DDS), polyvinylpyrrolidone (PVP), poly(vinylpyrrolidone-co-dimethyl maleic anhydride) [PVD], cancer therapy
Anti-Cancer Agents in Medicinal Chemistry
Title: Promotion of Optimized Protein Therapy by Bioconjugation as a Polymeric DDS
Volume: 6 Issue: 3
Author(s): Yasuhiro Abe, Hiroko Shibata, Haruhiko Kamada, Shin-Ichi Tsunoda, Yasuo Tsutsumi and Shinsaku Nakagawa
Affiliation:
Keywords: Polyethylene glycol (PEG), bioconjugation, drug delivery system (DDS), polyvinylpyrrolidone (PVP), poly(vinylpyrrolidone-co-dimethyl maleic anhydride) [PVD], cancer therapy
Abstract: In recent years, clinical applications of recombinantly produced bioactive proteins such as cytokines have attracted attention. However, since these recombinant proteins are rather unstable in vivo, their clinical use as therapeutic agents requires frequent administration at a high dosage. This regimen disrupts homeostasis and results in severe side effects. To overcome these problems, bioactive proteins have been conjugated with water-soluble synthetic (WSS) polymeric carriers. Chemical modification of a protein with a WSS polymeric carrier (bioconjugation) regulates tissue distribution, resulting in a selective increase in its desirable therapeutic effects and a decrease in undesirable side effects. Among several drug delivery system (DDS) technologies, bioconjugation has been recognized as one of the most efficient methods for improving therapeutic potency of proteins. However, for further enhancement of the therapeutic potency and safety of conjugated bioactive proteins, more precise regulation of the in vivo behavior of each protein is necessary for selective expression of its therapeutic effect. Therefore, alternative WSS polymeric modifiers in which new functions such as targeting and controlled release of drugs can be added are required for further development of bioconjugated drugs. Recently, we have synthesized a novel polymeric drug carrier, poly(vinylpyrrolidone-co-dimethyl maleic anhydride) [PVD], which was a powerful candidate drug carrier for cancer therapy. In this review, we introduce useful information that enabled us to design polymeric drug carriers and their application for protein therapy.
Export Options
About this article
Cite this article as:
Abe Yasuhiro, Shibata Hiroko, Kamada Haruhiko, Tsunoda Shin-Ichi, Tsutsumi Yasuo and Nakagawa Shinsaku, Promotion of Optimized Protein Therapy by Bioconjugation as a Polymeric DDS, Anti-Cancer Agents in Medicinal Chemistry 2006; 6 (3) . https://dx.doi.org/10.2174/187152006776930864
DOI https://dx.doi.org/10.2174/187152006776930864 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Radiation and Gene Therapy: Rays of Hope for the New Millennium?
Current Gene Therapy Antigenic Differences Between Normal and Malignant Cells as a Basis for Treatment of Intracerebral Neoplasms Using a DNA-Based Vaccine
Current Genomics Protein Kinase CK2 in Human Diseases
Current Medicinal Chemistry Development of Hedgehog Pathway Inhibitors (HPI) in Treatment of Cancer
Current Chemical Biology Therapeutic Outcomes in AIDS-Associated Kaposi's Sarcoma Patients on Antiretroviral Therapy Treated with Chemotherapy at Two Tertiary Hospitals in Lusaka, Zambia
Current HIV Research Alternate Strategies of Hsp90 Modulation for the Treatment of Cancer and Other Diseases
Current Topics in Medicinal Chemistry CRISPR/Cas9 Genome Editing Tool: A Promising Tool for Therapeutic Applications on Respiratory Diseases
Current Gene Therapy Gallium in Cancer Treatment
Current Topics in Medicinal Chemistry Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma
Current Pharmaceutical Design Gamma-Secretase as a Pharmacological Target in Alzheimer Disease Research: When, Why and How?
Current Pharmaceutical Design Clinical, Immunological and Therapeutic Aspects of Autoimmune Encephalitis
Recent Patents on CNS Drug Discovery (Discontinued) Properties of the Mesenchymal Endometriotic Stem Cell in the Context of the Immune System and Analysis of its Role in Endometriosis
Recent Patents on Regenerative Medicine Aflibercept (VEGF-TRAP): The Next Anti-VEGF Drug
Inflammation & Allergy - Drug Targets (Discontinued) Characterization of Molecular and Functional Alterations of Tumor Endothelial Cells to Design Anti-Angiogenic Strategies
Current Vascular Pharmacology ABC Transporter Inhibitors in Reversing Multidrug Resistance to Chemotherapy
Current Drug Targets Mammalian Target of Rapamycin (mTOR) Inhibitors as Anti-Cancer Agents
Current Cancer Drug Targets Signaling Intermediates (MAPK and PI3K) as Therapeutic Targets in NSCLC
Current Pharmaceutical Design Exploiting Internal Ribosome Entry Sites in Gene Therapy Vector Design
Current Gene Therapy Pancreatic Cancer and Personalized Medicine: Can Genomics Facilitate Early Diagnosis or Improve Therapeutic Outcomes?
Current Pharmacogenomics and Personalized Medicine A Novel Multiple Tyrosine-kinase Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Solid Tumors: Cabozantinib
Anti-Cancer Agents in Medicinal Chemistry